• The Joint Commission's 2026 National Performance Goals make language access a formal accreditation requirement, shifting vendor selection into compliance territory.

• A vendor without a SOC 2 Type II report, a BAA and a documented human oversight protocol on first request is not production-ready.
• Per-minute pricing is the wrong primary metric: total cost of language access per LEP encounter tells the real story.
• Dialect coverage is the variable that determines real-world clinical performance.
• The right vendor question is not "which is cheapest" but "which can scale with us without creating liability we cannot see."

Healthcare organizations are making AI interpretation commitments that will shape their language access programs for three to five years. Most RFP processes were not built for this. They ask the right questions about legacy modalities (phone, video, on-site) but miss the variables that distinguish mature AI platforms from early-stage products with a compelling demo.

This checklist is built for the executives who sign off on these contracts: CMOs, CIOs, Chief Compliance Officers and CFOs. It does not repeat what you already know about HIPAA or Title VI. It focuses on the six areas where AI interpreter vendor evaluation most commonly breaks down.

‍

What compliance and trust criteria define a clinical-grade AI interpretation vendor?

The baseline is non-negotiable. Any vendor being evaluated for clinical deployment must hold a current HIPAA Business Associate Agreement (BAA) and a SOC 2 Type II certification covering their production environment, not a pending report or a self-attestation. SOC 2 Type II provides independent auditor verification that security controls are operational over time, not just at a point in time.

Beyond the baseline, the 2026 Joint Commission National Performance Goals (NPGs) require qualified interpreters for high-stakes clinical interactions. A vendor who positions AI as a standalone solution for these encounters without a documented pathway to human oversight is out of compliance before you sign the contract.

What documentation should a vendor produce before shortlisting?

Request these five items before any demo:

• Current BAA template with data processing addendum
• SOC 2 Type II report with audit period clearly stated
• Human oversight protocol specifying how clinicians access a human interpreter within the same platform
• Encounter audit log sample showing utterance-level documentation
• Data retention and deletion policy with defined timelines

Vendors with production deployments in health systems have all of this ready within 48 hours. Vendors who do not are not production-ready.

‍

Does AI interpretation comply with Section 1557 of the Affordable Care Act?

Section 1557 of the Affordable Care Act (ACA), updated by HHS in 2024, requires qualified language assistance for LEP (Limited English Proficiency) patients in health programs receiving federal funding. It does not prohibit AI interpretation. A 2026 NEJM Catalyst study by Montoya Rubiano et al. at Brigham and Women's Hospital found that patients viewed AI and video remote interpretation as serving different clinical contexts, with AI preferred for speed and privacy and human interpreters preferred for emotionally complex conversations. The hybrid model is the compliant model.

‍

How should clinical accuracy be evaluated across your patient population?

Accuracy is not a single number. It is a function of language, dialect, medical domain and encounter type. A platform that performs at high accuracy across Spanish encounters may perform significantly lower on Haitian Creole, Marshallese or regional Arabic dialects because LLM performance is directly constrained by training data volume for each language. Ask vendors to provide validated accuracy data for the specific languages in your patient population, not aggregate benchmarks.

What is the difference between speech recognition accuracy and clinical interpretation accuracy?

Speech recognition accuracy measures whether the system correctly transcribes spoken words. Clinical interpretation accuracy measures whether the meaning, including medical terminology, symptom descriptions and treatment instructions, is preserved correctly in the target language. A system can have high speech recognition accuracy while still producing clinically unsafe interpretations. Evaluation should test both layers using clinical scenarios drawn from your own encounter types.

‍

How should dialect coverage factor into vendor evaluation?

Spanish alone covers regional variants, including Mexican, Dominican, Puerto Rican and Central American Spanish, that differ enough in medical vocabulary and cultural framing to affect clinical communication. Ask vendors specifically which dialects are supported and how performance is validated within each. A platform that maps all Spanish encounters to a single model is not the same as one that handles dialect at the interpretation layer.

‍

‍

What operational requirements should the RFP specify?

The most common gap in AI interpreter vendor evaluations is the failure to test failure modes. For interpretation specifically, the scenarios that matter most are:

• Patient speaks a dialect the AI does not recognize mid-encounter
• Patient requests a human interpreter: how many steps to reach one, does the session restart from zero
• Connectivity drops mid-session: what is the fallback behavior
• Clinician needs to pause interpretation during a side conversation with a colleague
• Platform is accessed from a device with no dedicated app installed

Vendors with production deployments will demo against all five. Vendors who redirect to the happy-path demo are signaling something.

‍

What should a pilot structure look like before full deployment?

Structure the pilot with explicit success criteria, a defined scope and a contract off-ramp if targets are not met. For AI interpretation, the five metrics worth tracking are:

• Time-to-interpreter in seconds from need to active session
• Clinician adoption rate at 30 and 60 days
• Patient satisfaction scores stratified by language
• Human interpreter requests per 100 AI encounters (a high rate signals AI is not meeting clinical expectations for specific encounter types)
• Encounter documentation completeness rate

‍

‍

How should pricing and financial transparency be evaluated?

Most legacy interpretation contracts charge by the minute. That model creates a perverse incentive: it penalizes thoroughness. Clinicians internalize the cost of language access and shorten encounters accordingly. Steamboat Pediatrics, a Colorado-based pediatric practice, switched to a flat monthly subscription and found that providers took the time each visit required without tracking cost per minute, budgeting language access as a predictable line item rather than a variable expense.

When comparing vendors on cost, total cost of language access is the right metric. That includes:

• Platform fee
• Staff time to manage the vendor relationship
• Coverage gaps requiring supplemental spending on phone or video interpretation
• Compliance gap costs that surface during audits or accreditation reviews
• Training and onboarding time per clinician cohort

The CFO question is not "what is the monthly fee" but "what does language access cost us per LEP encounter, fully loaded."

‍

What signals indicate a vendor is stable enough for a multi-year commitment?

The AI vendor market is moving faster than any previous healthcare technology cycle. For AI interpretation specifically, a vendor failure mid-contract means your LEP patients lose language access. Stability signals worth checking before signing:

• Production deployments in more than 20 health systems (not pilots)
• Minimum two to three years of operating history at clinical scale
• Named product leadership team with a published roadmap
• Participation in a recognized health innovation program with independent selection criteria

No Barrier's selection for the 2026 NACHC/ScaleHealth Accelerator Cohort, a nine-month structured program serving the 52 million Americans in Community Health Centers, is one example of institutional validation that signals independent review. The full announcement is on the NACHC website.

‍

Bottom line: How to run the executive evaluation

The six criteria above map to a simple sequence. Before issuing an RFP, require compliance documentation. During shortlisting, test accuracy against your actual patient population languages. During demos, run failure scenarios. During pilot, track time-to-interpreter and human override rate. During contract negotiation, compare total cost per LEP encounter. Post-contract, assign an executive owner for language access governance.

The vendors who hold up across all six are not common. That is the point of the checklist.

Reach out to No Barrier to apply this framework to your patient population and volumes. For a closer look at how the compliance layer translates into a working clinical deployment, the CHAI risk categorization framework is a practical starting point.